Logo image of 88Q.DE

4BASEBIO PLC (88Q.DE) Stock Fundamental Analysis

FRA:88Q - Deutsche Boerse Ag - GB00BMCLYF79 - Common Stock - Currency: EUR

13.2  0 (0%)

Fundamental Rating

3

Overall 88Q gets a fundamental rating of 3 out of 10. We evaluated 88Q against 71 industry peers in the Biotechnology industry. The financial health of 88Q is average, but there are quite some concerns on its profitability. While showing a medium growth rate, 88Q is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 88Q has reported negative net income.
88Q had a negative operating cash flow in the past year.
In the past 5 years 88Q always reported negative net income.
88Q had a negative operating cash flow in each of the past 5 years.
88Q.DE Yearly Net Income VS EBIT VS OCF VS FCF88Q.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of 88Q (-64.26%) is worse than 66.20% of its industry peers.
Industry RankSector Rank
ROA -64.26%
ROE N/A
ROIC N/A
ROA(3y)-43.45%
ROA(5y)-34.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
88Q.DE Yearly ROA, ROE, ROIC88Q.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

With a decent Gross Margin value of 67.19%, 88Q is doing good in the industry, outperforming 64.79% of the companies in the same industry.
88Q's Gross Margin has improved in the last couple of years.
88Q does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5YN/A
88Q.DE Yearly Profit, Operating, Gross Margins88Q.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

88Q does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 88Q remains at a similar level compared to 1 year ago.
The debt/assets ratio for 88Q is higher compared to a year ago.
88Q.DE Yearly Shares Outstanding88Q.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
88Q.DE Yearly Total Debt VS Total Assets88Q.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

An Altman-Z score of 2.10 indicates that 88Q is not a great score, but indicates only limited risk for bankruptcy at the moment.
88Q has a Altman-Z score of 2.10. This is in the better half of the industry: 88Q outperforms 67.61% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 2.1
ROIC/WACCN/A
WACC8.89%
88Q.DE Yearly LT Debt VS Equity VS FCF88Q.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 2.73 indicates that 88Q has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.73, 88Q is in the better half of the industry, outperforming 64.79% of the companies in the same industry.
88Q has a Quick Ratio of 2.53. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 88Q (2.53) is better than 66.20% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.53
88Q.DE Yearly Current Assets VS Current Liabilites88Q.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for 88Q have decreased strongly by -48.82% in the last year.
Looking at the last year, 88Q shows a very strong growth in Revenue. The Revenue has grown by 88.81%.
Measured over the past years, 88Q shows a small growth in Revenue. The Revenue has been growing by 3.08% on average per year.
EPS 1Y (TTM)-48.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.17%
Revenue 1Y (TTM)88.81%
Revenue growth 3Y3.08%
Revenue growth 5YN/A
Sales Q2Q%37.82%

3.2 Future

Based on estimates for the next years, 88Q will show a very negative growth in Earnings Per Share. The EPS will decrease by -10.06% on average per year.
88Q is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.42% yearly.
EPS Next Y-49.26%
EPS Next 2Y-23.97%
EPS Next 3Y-10.06%
EPS Next 5YN/A
Revenue Next Year120%
Revenue Next 2Y144.95%
Revenue Next 3Y162.07%
Revenue Next 5Y118.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
88Q.DE Yearly Revenue VS Estimates88Q.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
88Q.DE Yearly EPS VS Estimates88Q.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

88Q reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 88Q. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
88Q.DE Price Earnings VS Forward Price Earnings88Q.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
88Q.DE Per share data88Q.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A cheap valuation may be justified as 88Q's earnings are expected to decrease with -10.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.97%
EPS Next 3Y-10.06%

More info and screens

0

5. Dividend

5.1 Amount

88Q does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4BASEBIO PLC

FRA:88Q (5/30/2025, 7:00:00 PM)

13.2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-23 2024-09-23
Earnings (Next)N/A N/A
Inst Owners13.6%
Inst Owner ChangeN/A
Ins Owners10.94%
Ins Owner ChangeN/A
Market Cap204.60M
Analysts84.44
Price Target19.88 (50.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.8%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-11.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-26.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 340.5
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.04
BVpS-0.4
TBVpS-0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.19%
FCFM N/A
ROA(3y)-43.45%
ROA(5y)-34.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5YN/A
F-Score1
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 162.63%
Cap/Sales 286.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.53
Altman-Z 2.1
F-Score1
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)377.67%
Cap/Depr(5y)304.08%
Cap/Sales(3y)488.69%
Cap/Sales(5y)350.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.17%
EPS Next Y-49.26%
EPS Next 2Y-23.97%
EPS Next 3Y-10.06%
EPS Next 5YN/A
Revenue 1Y (TTM)88.81%
Revenue growth 3Y3.08%
Revenue growth 5YN/A
Sales Q2Q%37.82%
Revenue Next Year120%
Revenue Next 2Y144.95%
Revenue Next 3Y162.07%
Revenue Next 5Y118.42%
EBIT growth 1Y-37.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.61%
EBIT Next 3Y-12%
EBIT Next 5Y9.12%
FCF growth 1Y-61.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135.3%
OCF growth 3YN/A
OCF growth 5YN/A